Skip to main content
European Commission logo
English English
CORDIS - EU research results
CORDIS
CORDIS Web 30th anniversary CORDIS Web 30th anniversary
Content archived on 2024-05-27

Biosage coronavirus vector-based vaccine for prevention of foot-and-mouth disease

Objective

A previously developed bio safe transmissible gastroenteritis virus (TGEV) -based vector will be engineered to amplify foot-and-mouth disease cased proteins, to serve as a marked vaccine against FMD. In addition to the bio safety features of the TGEV-based vector, constructions will include exclusively FMDV protease JC and P1-2A (to produce virus-like particles in situate and or a fragment of 3D so that no FMDV can be produced. The TGEV chosen replicates in the enteric and respiratory tracts which are very adequate replication in the enteric and respiratory Antigen expression, immune responses, protection against challenge with virulentFMDV, and possible virus transmission after challenge will be examined using swine, one of the major animal hosts for FMDV. Constructs expressing 20 amino acid sequences of the major antigenic site of FMDV-O and FMDV-C will also be tested in an attempt to broader the immune response.

Call for proposal

Data not available

Coordinator

CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS
EU contribution
No data
Address
Universidad Autonoma de Madrid, Cantoblanco
28049 MADRID
Spain

See on map

Total cost
No data

Participants (5)